Schizophrenia Drugs Market Report

Schizophrenia Drugs Market Analysis, By Therapeutic Class (Second-Generation, Third-Generation Antipsychotics), By Treatment (Oral, Injectables), By Major Markets, And Segment Forecasts, 2016 - 2022

  • Report ID: GVR-2-68038-222-8
  • Number of Pages: 103
  • Format: Electronic (PDF)

Table of Contents

Chapter 1 Research Methodology
                 1.1. Information procurement
                 1.2. Information or Data Analysis
                     1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                 3.1 Chapter Summary
                     3.1.1 Disease Primer
                     3.1.2 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU 5)
Chapter 4 Global Market Overview
                 4.1 Chapter Summary
                 4.2 Introduction and Market Overview
                 4.3 Market, by Therapeutic Class
                 4.4 Market Size and Forecast
                 4.5 Sales Performance, by Drug Class
                 4.6 Market Shares Distribution
                 4.7 Market Dynamics Among Leading Brands
                 4.8 Patent Expiry Analysis
                 4.9 Schizophrenia Market: Drivers and Restraints
                     4.9.1. Drivers
                     4.9.2. Challenges
                 4.10. M&A, Deal Landscape (2013-2017 YTD)
                     4.10.1. Mergers & Acquisitions
                     4.10.2. Deals Landscape
                 4.11. Emerging Markets
                 4.12. Pricing and Reimbursement Scenario
                 4.13. Schizophrenia Sector SWOT
Chapter 5 Pipeline Intelligence
                 5.1. Pipeline Landscape
                     5.1.1. Leading Drugs in Development
                     5.1.2. Key R&D Trends
                 5.2. Pipeline Landscape
                     5.2.1. Late Stage Pipeline Drugs
                     5.2.2. Profiles of Disruptive Drugs
                     5.2.3. Global Pipeline Forecast
Chapter 6 Company Profiles
                 6.1. Chapter Summary -
                 6.2. Johnson & Johnson
                     6.2.1. Company Overview
                     6.2.2. Current Product Portfolio
                     6.2.3. Product Forecast Sales through 2022
                     6.2.4. Strategic Initiatives
                         6.2.4.1. Key Company News Flow
                     6.2.5. SWOT
                 6.3. Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals
                     6.3.1. Company Overview
                     6.3.2. Current Product Portfolio
                     6.3.3. Product Forecast Sales through 2022
                     6.3.4. Strategic Initiatives
                         6.3.4.1. Key Company News Flow
                     6.3.5. Catalysts and Event Calendar
                     6.3.6. Pipeline Analysis and Overview
                     6.3.7. SWOT
                 6.4. AstraZeneca
                     6.4.1. Company Overview
                     6.4.2. Current Product Portfolio
                     6.4.3. Product Forecast Sales through 2022
                     6.4.4. Strategic Initiatives
                         6.4.4.1. Key Company News Flow
                     6.4.5. SWOT
                 6.5. Eli Lilly
                     6.5.1. Company Overview
                     6.5.2. Current Product Portfolio
                     6.5.3. Product Forecast Sales through 2022
                     6.5.4. Strategic Initiatives
                         6.5.4.1. Key Company News Flow
                     6.5.5. SWOT
                 6.6. Alkermes
                     6.6.1. Company Overview
                     6.6.2. Current Product Portfolio
                     6.6.3. Product forecast sales through 2022
                     6.6.4. Strategic Initiatives
                         6.6.4.1. Key Company News Flow
                     6.6.5. Pipeline Analysis & Overview
                     6.6.6. SWOT
                 6.7. Sumitomo Dainippon Pharma
                     6.7.1. Company Overview
                     6.7.2. Current Product Portfolio
                     6.7.3. Product Forecast Sales through 2022
                     6.7.4. Strategic Initiatives
                         6.7.4.1. Key Company News Flow
                     6.7.5. Pipeline Analysis & Overview
                     6.7.6. Pipeline Forecast
                     6.7.7. SWOT
                 6.8. Pfizer
                     6.8.1. Company Overview
                     6.8.2. Current Product Portfolio
                     6.8.3. Product Forecast Sales through 2022
                     6.8.4. Strategic Initiatives
                         6.8.4.1. Key Company News Flow
                     6.8.5. Pipeline Analysis & Overview
                     6.8.6. SWOT
                 6.9. Vanda Pharmaceuticals
                     6.9.1. Company Overview
                     6.9.2. Current Product Portfolio
                     6.9.3. Product Forecast Sales through 2022
                     6.9.4. Strategic Initiatives
                         6.9.4.1. Key Company News Flow
                     6.9.5. SWOT
                 6.10. Allergan (Forest Labs)/ Geodon Ritcher
                     6.10.1. Company Overview
                     6.10.2. Current Product Portfolio
                     6.10.3. Product Forecast Sales through 2022
                     6.10.4. Strategic Initiatives
                         6.10.4.1. Key Company News Flow
                     6.10.5. SWOT
Chapter 7 Market Outlook
                 7.1. What the Future Holds
                 7.2. The Winners and Losers
                 7.3. Emerging Companies/New Technology Platforms
                 7.4. The Road Ahead


List of Tables

TABLE 1 Age and Gender-Specific Prevalence of Schizophrenia in the U.K.
TABLE 2 U.S. Patents for Current Schizophrenia Drugs
TABLE 3 Total and Per Patient Cost for Schizophrenia by Region
TABLE 4 R&D Pipeline Overview
TABLE 5 Late-Stage Pipeline
TABLE 6 Pipeline Forecast
TABLE 7 Johnson & Johnson- Product Forecast Sales through 2022
TABLE 8 Bristol-Myers Squibb/ Otsuka Pharma- Product Forecast Sales through 2022
TABLE 9 AstraZeneca- Product Forecast Sales through 2022
TABLE 10 Eli Lilly- Product Forecast Sales through 2022
TABLE 11 Alkermes- Product Forecast Sales through 2022
TABLE 12 Sumitomo Dainippon- Product Forecast Sales through 2022
TABLE 13 Pfizer- Product Forecast Sales through 2022
TABLE 14 Vanda Pharma- Product Forecast Sales through 2022
TABLE 15 Allergan- Product Forecast Sales through 2022


List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Positive Symptoms Associated with Schizophrenia
FIG. 8 Negative Symptoms Associated with Schizophrenia
FIG. 9 Cognitive Symptoms Associated with Schizophrenia
FIG. 10 Lifetime Risk of Schizophrenia
FIG. 11 Percentage of Schizophrenia Onset by Age and Gender
FIG. 12 Age and Gender-Specific Prevalence of Schizophrenia in the U.S.
FIG. 13 Age and Gender-Specific Incidence of Schizophrenia in the U.S.
FIG. 14 Age and Gender-Specific Prevalence of Schizophrenia in Europe
FIG. 15 Incidence of Schizophrenia Based on Ethnic Group in the U.K.
FIG. 16 Prevalence of Schizophrenia in Japan
FIG. 17 Regional Market Size 2016-2022
FIG. 18 Market Share, by Drug Class 2016-2022
FIG. 19 Market Share, by Mode of Administration- Oral vs LAIs 2016-2022
FIG. 20 Market Shares, by Company 2016-2022
FIG. 21 Schizophrenia Sector SWOT
FIG. 22 Johnson & Johnson SWOT Analysis
FIG. 23 Bristol-Myers Squibb/ Otsuka Pharma SWOT Analysis
FIG. 24 AstraZeneca SWOT Analysis
FIG. 25 Eli Lilly SWOT Analysis
FIG. 26 Alkermes SWOT Analysis
FIG. 27 Sumitomo Dainippon SWOT Analysis
FIG. 28 Pfizer SWOT Analysis
FIG. 29 Vanda Pharma SWOT Analysis
FIG. 30 Allergan SWOT Analysis

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon